Seelos Therapeutics (Nasdaq:SEEL) - Stock Price, News & Analysis

SEEL Stock Overview

SEEL fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Rewards

Risk Analysis

Highly volatile share price over the past 3 months

Earnings have declined by 20.9% per year over past 5 years

Shareholders have been substantially diluted in the past year

Does not have a meaningful market cap ($4M)

+ 2 more risks

Seelos Therapeutics, Inc. Competitors

Filament Health

OTCPK:FLHL.F

US$7.4m

Palisade Bio

NasdaqCM:PALI

US$5.3m

SciSparc

NasdaqCM:SPRC

US$3.3m

Target Group

OTCPK:CBDY

US$3.6m

Price History & Performance

Summary of all time highs, changes and price drops for Seelos Therapeutics
Historical stock prices
Current Share Price	US$0.29
52 Week High	US$49.80
52 Week Low	US$0.28
Beta	1.9
1 Month Change	-45.86%
3 Month Change	-73.31%
1 Year Change	-98.62%
3 Year Change	-99.85%
5 Year Change	-99.68%
Change since IPO	-99.75%

Recent updates

Seelos' expects to commence SLS-005 study in rare neurological disease in H1 2021, shares up 6%

Jan 06

Seelos Therapeutics' trehalose nabs Israel patent

Dec 21

Seelos Therapeutics (SEEL) files for $200M mixed shelf, shares down 8%

Dec 16

Seelos nabs US Orphan Drug status for SLS-005 in amyotrophic lateral sclerosis

Nov 19

Shareholder Returns

	SEEL	US Pharmaceuticals	US Market
7D	-15.5%	-0.6%	1.0%
1Y	-98.6%	10.6%	21.9%

Return vs Industry: SEEL underperformed the US Pharmaceuticals industry which returned 13.2% over the past year.

Return vs Market: SEEL underperformed the US Market which returned 24.9% over the past year.

Price Volatility

Is SEEL's price volatile compared to industry and market?
SEEL volatility
SEEL Average Weekly Movement	18.2%
Pharmaceuticals Industry Average Movement	9.7%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.8%
10% least volatile stocks in US Market	3.0%

Stable Share Price: SEEL's share price has been volatile over the past 3 months.

Volatility Over Time: SEEL's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2016	16	Raj Mehra	seelostherapeutics.com

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company’s lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012.

Seelos Therapeutics, Inc. Fundamentals Summary

How do Seelos Therapeutics's earnings and revenue compare to its market cap?
SEEL fundamental statistics
Market cap	US$3.91m
Earnings (TTM)	-US$37.88m
Revenue (TTM)	US$2.20m

1.8x

P/S Ratio

-0.1x

P/E Ratio

Is SEEL overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SEEL income statement (TTM)
Revenue	US$2.20m
Cost of Revenue	US$30.12m
Gross Profit	-US$27.91m
Other Expenses	US$9.97m
Earnings	-US$37.88m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-2.77
Gross Margin	-1,267.09%
Net Profit Margin	-1,719.56%
Debt/Equity Ratio	-42.4%

How did SEEL perform over the long term?

See historical performance and comparison

SEEL Stock Overview

Rewards

Risk Analysis

Seelos Therapeutics, Inc. Competitors

OTCPK:FLHL.F

US$7.4m

NasdaqCM:PALI

US$5.3m

NasdaqCM:SPRC

US$3.3m

OTCPK:CBDY

US$3.6m

Price History & Performance

Recent News & Updates

New major risk - Market cap size

Seelos Therapeutics, Inc. Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis Study with SLS-005 (IV Trehalose)

New major risk - Revenue and earnings growth

New major risk - Market cap size

Seelos Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $4.000001 million.

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $4.000001 million.

Recent updates

New major risk - Market cap size

Seelos Therapeutics, Inc. Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis Study with SLS-005 (IV Trehalose)

New major risk - Revenue and earnings growth

New major risk - Market cap size

Seelos Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $4.000001 million.

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $4.000001 million.

Consensus EPS estimates upgraded to US$0.41 loss

Seelos Therapeutics, Inc. Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002

Chief Financial Officer recently bought US$100k worth of stock

New major risk - Market cap size

Seelos Therapeutics, Inc. has completed a Follow-on Equity Offering.

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering.

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

Consensus EPS estimates upgraded to US$0.34 loss

Seelos Therapeutics Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2)

Seelos Therapeutics Receives Non-Compliance Notice From Nasdaq

New major risk - Revenue and earnings growth

Consensus revenue estimates decrease by 26%

Seelos Therapeutics, Inc. Announces Top Line Results from SLS-002 Phase II Study in Adults with Major Depressive Disorder at Imminent Risk of Suicide

Consensus revenue estimates increase by 80%, EPS downgraded

Seelos Therapeutics, Inc. Announces the Close of Enrollment of Its Registration Directed Study of Sls-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior (Asib) in Adults with Major Depressive Disorder (MDD)

Listing Qualifications Staff of Nasdaq Provides Notice to Seelos Therapeutics for Not Regain Compliance with Rule 5550(a)(2) and Not Eligible for Second 180 Calendar Day Compliance Period

Price target decreased by 12% to US$5.50

No longer forecast to breakeven

Seelos Therapeutics Announces Completion of Enrollment of its Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform

Seelos Therapeutics Doses First Patients in an Ethnobridging Study with Sls-002 (Intranasal Racemic Ketamine)

Seelos Therapeutics, Inc. Announces Data Demonstrating Downregulation of Alpha Synuclein in an In Vivo Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 in Parkinson's Disease

Seelos Therapeutics Receives Written Notice of Non-Compliance from Nasdaq

Price target decreased to US$5.80

Seelos Therapeutics Doses First Patient in A Registrational Phase II/III Study of SLS-005 in Spinocerebellar Ataxia

Seelos: Data This Year Is Critical

Seelos Therapeutics Inc. Receives A Research and Development Grant from the Michael J. Fox Foundation for Parkinson's Research for SLS-004

Seelos wins Parkinson’s research grant for gene therapy program

Seelos Therapeutics, Inc. Announces Data Demonstrating Statistically Significant Downregulation of mRNA and Reduction of Alpha Synuclein in Vitro Gene Therapy Study

Seelos Therapeutics, Inc. Receives Notice of Allowance in U.S. for an Additional Patent for SLS-007

Price target decreased to US$4.25

Seelos Therapeutics Receives Written Notice from The Nasdaq Stock Market LLC Regarding Minimum Bid Price Requirement

Seelos Therapeutics, Inc., Annual General Meeting, May 20, 2022

Founder recently bought US$57k worth of stock

Price target decreased to US$6.83

Seelos Therapeutics, Inc. Announces Dosing of the First Participants in a Registrational Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform

Seelos: FDA Action Makes It Highly Attractive

Seelos Therapeutics, Inc. announced that it has received $20 million in funding from The Lind Partners, LLC

High number of new and inexperienced directors

High number of new and inexperienced directors

Seelos Therapeutics: Shares Have Finally Found A Floor But Risk Remains

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Director Judith Dunn has left the company

Price target decreased to US$8.58

We're Hopeful That Seelos Therapeutics (NASDAQ:SEEL) Will Use Its Cash Wisely

Seelos: Superior Data, But Early Stage

Seelos Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $60.000004 million.

Seelos Therapeutics, Inc. Announces Positive Data from the Open-Label Study of SLS-002

New 90-day high: US$4.75

Seelos Therapeutics Announces Completion of Open-Label Patient Enrollment of Proof of Concept Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder

Seelos Therapeutics Announces Amendment of SLS-002 Agreement to Repurchase a Significant Portion of Royalties for SLS-002 (Intranasal Racemic Ketamine Program)